Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance)

Jonathan E. Rosenberg, Karla A. Ballman, Susan Halabi, Pamela J. Atherton, Amir Mortazavi, Christopher Sweeney, Walter M. Stadler, Benjamin A. Teply, Joel Picus, Scott T. Tagawa, Sreedhar Katragadda, Daniel Vaena, Jamal Misleh, Christopher Hoimes, Elizabeth R. Plimack, Thomas W. Flaig, Robert Dreicer, Dean Bajorin, Olwen Hahn, Eric J. SmallMichael J. Morris

Cancer Epigenetics Institute
Hematology Oncology
Nuclear Dynamics and Cancer (NDC)

Memorial Sloan-Kettering Cancer Center
Cornell University
Duke University
Mayo Clinic
Ohio State University
Harvard University
University of Chicago
University of Nebraska Medical Center
Washington University St. Louis
Cone Health Cancer Center
University of Iowa
Christiana Care Health System
Case Western Reserve University
University of Colorado Anschutz Medical Campus
University of Virginia
University of California at San Francisco

Research output: Contribution to journal › Article › peer-review

30 Scopus citations

Sort by
Weight
Alphabetically

Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance)

Fingerprint

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science